, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Lantheus class action lawsuit – captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities and charges Lantheus as well as certain of Lantheus's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Lantheus class action l ...

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. by Berger Montague PC on behalf of investors who acquired KBR shares during the specified class period, alleging that KBR made false and misleading statements regarding its partnership with HomeSafe and the performance under the Global Household Goods Contract [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that KBR failed to disclose material concerns raised by the U.S. Department of Defense's TRANSCOM about HomeSafe's ability to fulfill its obligations [3]. - KBR publicly asserted that its partnership with HomeSafe was functioning well and poised for growth, despite the ongoing concerns [3]. - Following the announcement of the contract termination by HomeSafe on June 19, 2025, KBR's stock price dropped by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 2: Company Overview - KBR, Inc. is headquartered in Houston, Texas, and provides services in engineering, logistics, defense contracting, and mission-critical government services [2].

Core Viewpoint - The KinderCare Learning Companies, Inc. is facing a class action lawsuit related to its October 2024 IPO, alleging violations of the Securities Act of 1933 due to misleading information regarding child care quality and incidents of abuse at its facilities [1][4]. Group 1: IPO Details - KinderCare sold over 27 million shares at $24 per share during its IPO, raising a total of $648 million in gross proceeds [3]. - Following the IPO, KinderCare's stock price has significantly declined to lows near $9 per share [5]. Group 2: Allegations in the Lawsuit - The lawsuit claims that the registration statement for the IPO was false and misleading, failing to disclose numerous incidents of child abuse and neglect at KinderCare facilities [4]. - It is alleged that KinderCare did not provide the "highest quality care possible" and failed to meet basic standards in the child care industry, exposing the company to undisclosed risks of lawsuits and reputational damage [4]. Group 3: Legal Process - Investors who purchased KinderCare common stock in or traceable to the IPO have until October 14, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][6]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in securing monetary relief for investors, being ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years [7].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc for alleged violations of federal securities laws, impacting investors who acquired Marex securities between May 16, 2024, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Marex made materially false and misleading statements and failed to disclose conflicts of interest related to over-the-counter financial products sold to itself [3]. - It is alleged that Marex's financial statements contained significant inconsistencies between subsidiaries and related parties, leading to unreliable financial reporting [3]. - The lawsuit asserts that the public statements made by Marex regarding its business and financial condition were false and misleading throughout the class period, resulting in investor damages when the truth emerged [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Marex have until December 8, 2025, to request appointment as lead plaintiff in the class action [4]. - A copy of the Complaint can be reviewed on the law firm's website, and interested parties can contact the firm for more information [4]. Group 3: Legal Representation - The law firm Bronstein, Gewirtz & Grossman operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if the case is successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. for alleged violations of federal securities laws during the specified class period [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased aTyr securities between January 16, 2025, and September 12, 2025 [2]. - The Complaint alleges that aTyr's executives made materially false and misleading statements regarding the drug Efzofitimod, particularly about its efficacy and the ability for patients to taper steroid usage [3]. Group 2: Next Steps for Investors - Investors who suffered losses in aTyr have until December 8, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - A class action lawsuit has been filed against WPP plc and certain officers for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased WPP securities between February 27, 2025, and July 8, 2025 [2]. - The Complaint alleges that WPP's management made materially false and misleading statements regarding the company's media operations, while concealing adverse facts about its performance and market share [3]. Group 2: Allegations Against WPP - Defendants allegedly provided overly positive statements about WPP's media arm, while failing to disclose its inability to manage macroeconomic challenges and competition effectively [3]. - The media arm of WPP reportedly began losing significant market share to competitors, which was not disclosed to investors [3]. - The misleading statements led to shareholders purchasing WPP securities at artificially inflated prices [3]. Group 3: Next Steps for Investors - Investors who suffered losses in WPP have until December 8, 2025, to request to be appointed as lead plaintiff in the class action [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 4: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered substantial amounts for investors [6].

Core Viewpoint - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the impact of the Affordable Connectivity Program's termination on the company's customer base and earnings [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Sandoval v. Charter Communications, Inc., No. 1:25-cv-06747, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until October 14, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Charter is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program (ACP), which provided funding to subsidize high-speed internet plans for low-income households [3]. - The ACP ended in June 2024 due to a lack of federal funding, leading to customer declines for Charter [3]. Group 3: Financial Impact - During the relevant period, Charter claimed to have successfully managed the risks associated with the end of the ACP, stating that the impact was behind them [4]. - However, the company continued to experience declines in internet customers and revenue, contradicting its earlier statements [4]. - In Q2 2025, Charter reported a decrease of 117,000 total internet customers, with approximately 50,000 disconnects attributed to the end of the ACP, nearly double the disconnects from the previous quarter [5]. - Following this announcement, Charter's stock price fell by $70.25 per share, or 18.4%, from $380.00 on July 24, 2025, to $309.75 on July 25, 2025 [5].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company that provides managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was able to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding a challenging medical cost trend environment, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with claims that the company misrepresented its financial health and ability to manage macroeconomic challenges during a specified class period [1][3]. Summary by Sections Class Action Lawsuit Details - The lawsuit, titled Sarti v. Dow Inc., allows purchasers of Dow securities from January 30, 2025, to July 23, 2025, to seek lead plaintiff status by October 28, 2025 [1]. - The allegations include that Dow overstated its ability to handle macroeconomic and tariff-related challenges and understated the negative impacts on its business [3]. Financial Performance and Market Reactions - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, citing ongoing weakness in key markets [4]. - Following this downgrade, Dow's stock price fell by over 3% [4]. - On July 24, 2025, Dow reported a non-GAAP loss per share of $0.42, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [5]. - Dow's CEO attributed the disappointing results to a challenging earnings environment and announced a dividend cut from $0.70 to $0.35 per share, leading to a stock price drop of over 17% [5]. Legal Process for Lead Plaintiff - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Dow securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives failed to disclose critical information regarding financial performance and medical cost trends, leading to significant stock price declines during the class period [1][3][4]. Summary by Sections Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and covers purchasers of Molina Healthcare securities from February 5, 2025, to July 23, 2025, with a deadline of December 2, 2025, for lead plaintiff applications [1][2]. Allegations Against Molina Healthcare - The lawsuit claims that Molina Healthcare did not disclose adverse facts about its medical cost trend assumptions, the dislocation between premium rates and medical costs, and the dependency of near-term growth on low utilization of various health services [3]. - It is alleged that Molina Healthcare's financial guidance for fiscal year 2025 was likely to be cut due to these undisclosed issues [3]. Financial Performance and Stock Impact - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines, leading to a 10.2% cut in earnings guidance [4]. - Following the financial results announcement on July 23, 2025, Molina Healthcare reported GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and revised its full-year 2025 adjusted earnings expectation to no less than $19.00 per diluted share, resulting in a nearly 17% drop in stock price [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Molina Healthcare securities during the class period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7][8].